Regeneron Pharmaceuticals, Inc. Stock price

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 09:57:21 2024-03-28 am EDT 5-day change 1st Jan Change
965.2 USD -0.12% Intraday chart for Regeneron Pharmaceuticals, Inc. -0.21% +9.99%
Sales 2024 * 13.89B Sales 2025 * 14.91B Capitalization 104B
Net income 2024 * 4.26B Net income 2025 * 4.54B EV / Sales 2024 * 6.84 x
Net cash position 2024 * 8.91B Net cash position 2025 * 12.78B EV / Sales 2025 * 6.11 x
P/E ratio 2024 *
26.5 x
P/E ratio 2025 *
24.8 x
Employees 13,450
Yield 2024 *
-
Yield 2025 *
-
Free-Float 77.74%
More Fundamentals * Assessed data
Dynamic Chart
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals MT
Regeneron Shares Down After FDA Letter Questioning Application for Potential Lymphoma Treatment MT
FDA Rejects Regeneron's Odronextamab in Follicular, Diffuse Large B-cell Lymphoma DJ
US FDA declines to approve Regeneron's blood cancer therapy RE
Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab CI
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals MT
Intellia Therapeutics Ends Co-Development Agreement With Regeneron DJ
US appeals court revives Regeneron's antitrust lawsuit against Novartis RE
US appeals court revives Regeneron's antitrust lawsuit against Novartis RE
Regeneron Pharmaceuticals Insider Sold Shares Worth $5,531,290, According to a Recent SEC Filing MT
2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene Therapy DJ
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-13-2024 10:40 AM
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,115 From $1,104, Maintains Overweight Rating MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 11:15 AM
Regeneron Says FDA Extends Approval of Praluent to Treat Children, Teens With Genetic High-Cholesterol MT
More news
1 day+0.29%
1 week-0.07%
Current month+0.02%
1 month-2.72%
3 months+10.51%
6 months+16.06%
Current year+10.02%
More quotes
1 week
952.47
Extreme 952.4651
977.39
1 month
947.37
Extreme 947.3661
990.30
Current year
871.39
Extreme 871.39
998.33
1 year
684.81
Extreme 684.805
998.33
3 years
469.36
Extreme 469.36
998.33
5 years
271.37
Extreme 271.37
998.33
10 years
269.50
Extreme 269.5
998.33
More quotes
Managers TitleAgeSince
Founder 64 88-01-07
Chief Executive Officer 71 88-01-07
Director of Finance/CFO 54 02-12-31
Members of the board TitleAgeSince
Director/Board Member 71 10-11-11
Chief Executive Officer 71 88-01-07
Director/Board Member 82 91-05-31
More insiders
Date Price Change Volume
24-03-28 966 -0.03% 11 308
24-03-27 966.3 +0.29% 314,755
24-03-26 963.6 +0.26% 386,837
24-03-25 961.1 -0.64% 322,288
24-03-22 967.2 -0.08% 274,406

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
966.3 USD
Average target price
1,022 USD
Spread / Average Target
+5.78%
Consensus
  1. Stock
  2. Equities
  3. Stock Regeneron Pharmaceuticals, Inc. - Nasdaq